1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Pharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia

Pharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia

  • April 2016
  • 216 pages
  • ID: 3874358
  • Format: PDF
  • By Visiongain

Summary

Table of Contents

Report Details
Leading Stem Cell Companies – Discover What Their Futures Hold, Benefiting Your Reputation for Commercial Insight
Who are the leading stem cell developers and producers? And what are their sales outlooks? Visiongain’s updated report shows you their activities and potentials from 2016. There you discover therapies, results, trends in research and development, opportunities and revenue forecasts.

That way you explore data and discussions on cellular technologies transforming human medicine. Our study analyses 25 leading companies in the US, Europe, Israel and Asia-Pacific. There you hear how stem cell producers can progress and gain. Discover their potentials and see what the future holds.

Please read on, then, to scan those organisations and find what revenue that fast-growing and potentially large market could generate in future. See what is possible.

Forecasts and other data to benefit your authority on stem cell biotechnology
In our study you find profiles of 25 prominent stem cell companies and analyses of their industry. You explore sales results, R&D and revenue forecasting. Explore, from 2016, those firms’ capabilities, portfolios and commercial prospects.

In our updated report you gain 55 tables, 24 charts and two interviews with that industry. You see our discussions with authorities from Mesoblast and Gamida Cell.

With our study you could help your research, analyses and decisions, also saving time. And see how you could benefit your reputation for commercial insight.

Stay ahead, then, for knowledge on that vast, rising industry. The following sections explain how our new investigation benefits your work.

United States (US) – assess leading organisations, seeing what is possible
First our study gives you discussions, analyses and commercial outlooks for 11 US-based stem cell companies:
- Osiris Therapeutics
- Caladrius Biosciences
- Orthofix
- NuVasive
- AlloSource
- RTI Surgical
- Vericel Corporation
- U.S. Stem Cell, Inc.
- Neuralstem
- Astellas/Ocata Therapeutics
- Athersys

There you hear what the future holds for those cellular biology companies, including regulations, research trends and some revenue predictions.

Our study then analyses Asian organisations, explaining that region’s potential.

Stem cell specialists based in the Asia Pacific region – what developments possible?
You also discover commercial outlooks for six top researchers, developers and producers of stem cells in the Asia Pacific region:
- Mesoblast
- Reliance Life Sciences
- Anterogen
- Pharmicell
- MEDIPOST
- Stempeutics.

Our analyses show possibilities for advancing technology and raising business performance, assessing where future sales expansion is possible. Explore regulations and see how companies progress, assessing revenue potentials.

The report then analyses Europe and Israel, showing those countries’ activities and potentials.

Companies based in Europe and Israel – what successes can they achieve?
Our analysis also shows you progress and prospects for eight European and Israeli companies:
- TiGenix
- Celyad
- Apceth
- ReNeuron
- Gamida Cell
- Cell Cure Neurosciences
- Pluristem Therapeutics
- BrainStorm Cell Therapeutics.

Many opportunities arise in that industry, with high, expanding revenues possible from this decade. In our study you also explore clinical testing and plans for launching products.

Predictions for the worldwide stem cells market – see that industry’s sales potential
Our report also forecasts sales to 2026 for the overall world stem cells industry. There you find revenues reaching $17.8bn in 2020, with high growth to 2026.

In our study you also gain revenue forecasting to 2026 for these products:
- Trinity Elite and Trinity Evolution
- Osteocel Plus
- MSC-100-IV
- CardioRel
- Hearticellgram-AMI
- Cartistem.

See there how applications of stem cells can perform. Find, from 2016, where those organisations can generate high sales. That industry holds vast potential.

With our report you assess how stem cell companies can compete and succeed. See what their future holds and how you can gain.

Technologies and issues shaping that industry and market – what is happening?
Our study explains stem cell technologies and forces influencing that industry and market. There you explore developments and forces, including these:
- Sales potentials of leading stem cell therapies to 2026 – see what is possible
- Embryonic stem cells – potentials in tissue repair and regenerative medicine
- Autologous and allogeneic agents, including T cell therapy
- Advances in treating eye disorders, e.g. age-related macular degeneration (AMD)
- Novel treatments for cancer and other applications – e.g. diabetes and bone re-growth – including progress of clinical trials and product launches.

With that work you assess these influences, too, among others:
- Regulations for that research and its applications – see what countries do
- Umbilical cord blood – applications and approvals for that tissue and cell banking
- Mergers, acquisitions, alliances and venture capital – explore what shapes that industry and affects its future
- Non-therapeutic pharma applications – screening and toxicity studies in drug development.

In our survey you also find interviews with two companies – Mesoblast and Gamida Cell. There gain information to help you stay ahead in knowledge on challenges, progress, potentials and future trends.

See what is possible, then, for that cell-based biotechnology and explore what its future holds.

Ways Pharma Leader Series: Top Stem Cell Companies Report 2016-2026 helps you
In particular, our independent analysis gives you this knowledge to benefit your work:
- Profiles of 25 leading stem cell companies in North America, Europe, Israel and Asia – assess products, R&D, results, strategies, alliances and sales outlooks
- Revenue forecasting to 2026 for that overall world market – discover potential sales, exploring those technologies’ commercial prospects
- Forecast revenues to 2026 for leading stem cell products – see how top companies’ technologies can compete and succeed
- Opportunities, competition and demands – explore what affects companies, finding what influences sales and shapes organisations’ futures
- Interviews with companies in that industry – find what participants say and do, helping you stay ahead in knowledge and benefit your influence.

That report, by visiongain’s in-house analysts in the UK, gives knowledge to benefit your work. Its purpose is to help you save time and avoid struggles to find information. You gain analysis to benefit your plans, decisions and presentations.

Data found nowhere else, benefiting your research, analyses and proposals
Our report gives independent analysis. There you get competitive intelligence found only in that work, assessing commercial potentials. Explore what the future holds.

With our analysis you are less likely to fall behind in information or miss opportunity. There see how you could save time and effort. So benefit your plans, decisions and influence now, helping you gain advantages and succeed.

By trying our latest study on stem cells, you explore trends, R&D and sales predictions. You assess the present and future of companies. Avoid missing out on data and discussions to help you stay ahead. So please get our new report here now.

Please note: This report is accessed through a password system. Single user (non-printable) and departmental licenses expires after 12 month period.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019, provides an overview ...

Global Gene Therapy Partnering Terms and Agreements 2014 to 2019

Global Gene Therapy Partnering Terms and Agreements 2014 to 2019

  • $ 2995
  • December 2019

The Global Gene Therapy Partnering Agreements 2014-2019 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.Trends ...

Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019

Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Clinical Chemistry Rapid Tests & Point-of-Care (POC) Diagnostic Tests - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Clinical Chemistry Rapid Tests & Point-of-Care ...

Uveitis - Pipeline Review, H2 2019 $ 2000 November 2019


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on